Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
SHANGHAI, China, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and Korea. BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine. Karl Lintel, M.D., Chief Executive Officer of BioShin commented, “We are very pleased to have started enrollment in study BHV300-310. Rimegepant was launched in...
For his second "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer spoke with Vlad Coric, CEO of Biohaven Pharmaceutical Holding Co. , makers of the breakthrough migraine drug, Nurtec ODT. Shares of BHVN have tripled since Cramer last checked in back in April. Coric said they've seen explosive growth in Nurtec since its debut with prescriptions surging over 200,000.
Up to 55% of migraine patients do not have sufficient relief with currently available treatments.2 NURTEC™ ODT (rimegepant) can work quickly, returning patients to normal function in as little as one hour.1 NURTEC ODT's manufacturer, Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and pharmacy benefit manager Prime Therapeutics LLC (Prime) recently entered into a value-based contract agreement to help ensure that relief truly comes for patients.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that Dr. Richard Granstein, M.D., Chairman of Dermatology at Weill Cornell Medicine in New York City, will initiate an investigator-led clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases including spinocerebellar ataxia, today announced its partnership with the National Ataxia Foundation (NAF) to help the nonprofit organization launch the NAF Drug Development Collaborative. As the first pharmaceutical industry member to commit su...
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share decreased 30.88% year over year to ($2.67), which beat the estimate of ($2.89).Revenue of $17,664,000 up by 0.00% year over year, which missed the estimate of $19,840,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Nov 09, 2020View more...
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tumor therapeutic agent created with the company’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform. The data were presented at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting...